Cardiff Oncology Inc

Real-time Quotes | Nasdaq Last Sale

After Hours: 22.20 +0.28 +1.28% 14:49 11/27 EST
Corp Actions
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 4d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 5d ago
Cardiff Oncology to Participate in Fireside Chat at the Piper Sandler 32nd Annual Healthcare Conference
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing a drug to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-resistant prostate cancer and leukemia, today announced that the Company will be participating in the upcoming Piper Sandler 32nd Annual Virtual Healthcare Conference. Beginning today, November 23rd, a pre-recorded fireside chat with company management will be available for viewing anytime through December 3rd by accessing the recording library on the Piper Sandler conference site.
PR Newswire · 6d ago
Cardiff Oncology EPS in-line, beats on revenue
Cardiff Oncology (CRDF): Q3 GAAP EPS of -$0.19 in-line.Revenue of $0.14M (+180.0% Y/Y) beats by $0.11M.Press Release
Seekingalpha · 11/05 22:10
Have Insiders Been Buying Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares?
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Simply Wall St. · 10/25 14:19
Align Technology, Bio-Path Holdings leads healthcare gainers; InVivo Therapeutics, Teligent among major losers
Gainers: Align Technology (ALGN) +33%, Bio-Path Holdings (BPTH) +23%, Brainstorm Cell Therapeutics (BCLI) +13%, Beam Therapeutics (BEAM) +13%, Cardiff Oncology (CRDF) +10%.Losers: InVivo Therapeutics (NVIV) -45%, Teligent (TLGT) -27%, Aptinyx (APTX) -21%, Iterum Therapeutics (ITRM) -20%, Timber Pharmaceuticals (TMBR) -18%.
Seekingalpha · 10/22 15:04
Hudson Technologies to Host Conference Call to Discuss Third Quarter 2020 Results
PEARL RIVER, N.Y., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Hudson Technologies, Inc. (NASDAQ: HDSN) will host a conference call and webcast on Thursday, November 5, 2020 at 5:00 p.m. Eastern Time to discuss the Company’s third quarter results. To access the live webcast, log onto the Hudson Technologies website at, and click on “Investor Relations”.To participate in the call by phone, dial (844) 602-0380 approximately five minutes prior to the scheduled start time. International callers please dial (862) 298-0970.A replay of the teleconference will be available until December 5, 2020 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 38281.  About Hudson Technologies         Hudson Technologies, Inc. is a leading provider of innovative and sustainable solutions for optimizing performance and enhancing reliability of commercial and industrial chiller plants and refrigeration systems. Hudson's proprietary RefrigerantSide® Services increase operating efficiency, provide energy and cost savings, reduce greenhouse gas emissions and the plant’s carbon footprint while enhancing system life and reliability of operations at the same time. RefrigerantSide® Services can be performed at a customer's site as an integral part of an effective scheduled maintenance program or in response to emergencies. Hudson also offers SMARTenergy OPS®, which is a cloud-based Managed Software as a Service for continuous monitoring, Fault Detection and Diagnostics and real-time optimization of chilled water plants. In addition, the Company sells refrigerants and provides traditional reclamation services for commercial and industrial air conditioning and refrigeration uses. For further information on Hudson, please visit the Company's web site at Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995Statements contained herein which are not historical facts constitute forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.  Such factors include, but are not limited to, changes in the laws and regulations affecting the industry, changes in the demand and price for refrigerants (including unfavorable market conditions adversely affecting the demand for, and the price of, refrigerants), the Company's ability to source refrigerants, regulatory and economic factors, seasonality, competition, litigation, the nature of supplier or customer arrangements that become available to the Company in the future, adverse weather conditions, possible technological obsolescence of existing products and services, possible reduction in the carrying value of long-lived assets, estimates of the useful life of its assets, potential environmental liability, customer concentration, the ability to obtain financing, the ability to meet financial covenants under existing credit facilities, any delays or interruptions in bringing products and services to market, the timely availability of any requisite permits and authorizations from governmental entities and third parties as well as factors relating to doing business outside the United States, including changes in the laws, regulations, policies, and political, financial and economic conditions, including inflation, interest and currency exchange rates, of countries in which the Company may seek to conduct business, the Company’s ability to successfully integrate any assets it acquires from third parties into its operations, the impact of the current COVID-19 pandemic, and other risks detailed in the Company's 10-K for the year ended December 31, 2019 and other subsequent filings with the Securities and Exchange Commission. The words "believe", "expect", "anticipate", "may", "plan", "should" and similar expressions identify forward-looking statements.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made. Investor Relations Contact: John Nesbett/Jennifer Belodeau IMS Investor Relations (203) 972-9200 Company Contact: Brian F. Coleman, President & CEO Hudson Technologies, Inc. (845) 735-6000
GlobeNewswire · 10/22 13:30
Cardiff Oncology's onvansertib may overcome Zytiga resistance in prostate cancer
New efficacy data from ongoing Phase 2 trial of Cardiff Oncology's (CRDF) onvansertib in combination with J&J's Zytiga (abiraterone) and prednisone for metastatic castration-resistant prostate cancer, achieves the primary endpoint of disease control in patients showing initial
Seekingalpha · 10/20 13:16
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CRDF. Analyze the recent business situations of Cardiff Oncology Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CRDF stock price target is 26.25 with a high estimate of 30.00 and a low estimate of 23.00.
Institutional Holdings
Institutions: 88
Institutional Holdings: 18.73M
% Owned: 53.02%
Shares Outstanding: 35.32M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Biotechnology & Medical Research
Pharmaceuticals & Medical Research
Key Executives
Chairman/Executive Director
Thomas Adams
Chief Executive Officer/Director
Mark Erlander
Independent Director
James Armitage
Independent Director
Paul Billings
Independent Director
John Brancaccio
Independent Director
Gary Jacob
Independent Director
Rodney Markin
Independent Director
Gary Pace
Independent Director
Lale White
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CRDF
Cardiff Oncology Inc., formerly Trovagene, Inc., is a clinical-stage biotechnology company. The Company is focused on developing treatment options for cancer patients. It is developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics. Its clinical programs include KRAS-Mutated Metastatic Colorectal Cancer (mCRC), Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC) and relapsed or refractory Acute Myeloid Leukemia (AML). Its programs include the development of onvansertib in a Phase-I b/2 study of onvansertib in combination with FOLFIRI/Avastin in mCRC; a Phase II study of onvansertib in combination with Zytiga (abiraterone)/prednisone in Zytiga-resistant mCRPC, and a Phase-II study of onvansertib in combination with decitabine in AML.
Hot Stocks

Webull offers kinds of Cardiff Oncology Inc stock information, including NASDAQ:CRDF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRDF stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CRDF stock methods without spending real money on the virtual paper trading platform.